Canada· CA-DIN-02387034
ADREVIEW
A iobenguane (123i) product containing iobenguane 123 i, registered in Canada by GE HEALTHCARE CANADA INC. The same ATC class is registered in 9 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Iobenguane (123i) is registered in 9 of 19 countries.
Countries holding a registration under ATC V09IX01 (iobenguane (123i)), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 5 of them publish a price we can compare per daily dose
Iobenguane (123i) · ATC V09IX01
9 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- IOBENGUANE 123 I
- Manufacturer
- GE HEALTHCARE CANADA INC
- Country
- Canada (CA)
- ATC code
- V09IX01
- ATC class
- Iobenguane (123I)
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
241 interactions on record for iobenguane (123i).
Graded by severity as the source publishes them — 143 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Iobenguane (123i) · interactions on record
241 records
- 143 severe
- 98 moderate
Most severe, free to view
- PhentermineA08AA01severe
- FenfluramineA08AA02severe
- DexfenfluramineA08AA04severe
- MazindolA08AA05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under V09IX01
Iobenguane (123i), as other registers publish it.
- BelgiumAdreview 74 MBq/mlGE Healthcare
- SwitzerlandAdreView Iobenguane (I-123)
- NetherlandsAdreView, Iobenguane (123I) Injection, oplossing voor injectie 74 MBq/mlGE Healthcare B.V.
- SwitzerlandAdreView, Iobenguane (I-123) Injectionmedeo AG
- SwitzerlandAdreView, Iobenguane (I-123) Injectionmedeo AG
- SwitzerlandAdreView, Iobenguane (I-123) Injectionmedeo AG
- SwitzerlandAdreView, Iobenguane (I-123) Injectionmedeo AG
- SwitzerlandAdreView, Iobenguane (I-123) Injectionmedeo AG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0fafdcab-8f81-4854-bf40-217d92031f24 GET /v1/drugs/0fafdcab-8f81-4854-bf40-217d92031f24?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02387034",
"form": "SOLUTION",
"class": "Radiopharmaceutical",
"routes": [
"INTRAVENOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "V09IX01",
"schedule": [
"Schedule C"
],
"drug_code": "87259",
"strengths": [
"74 MBq"
],
"ahfs_class": null,
"substances": [
"IOBENGUANE 123 I"
],
"product_categorization": null
}See everything about iobenguane (123i).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.